- Home
- STTK vs FBLG Comparison
STTK vs FBLG Comparison
Compare STTK & FBLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- FBLG
- Stock Information
- Founded
- STTK 2016
- FBLG 2021
- Country
- STTK United States
- FBLG United States
- Employees
- STTK N/A
- FBLG N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- FBLG
- Sector
- STTK Health Care
- FBLG
- Exchange
- STTK Nasdaq
- FBLG NYSE
- Market Cap
- STTK 56.8M
- FBLG 91.0M
- IPO Year
- STTK 2020
- FBLG 2024
- Fundamental
- Price
- STTK $1.16
- FBLG $1.91
- Analyst Decision
- STTK Hold
- FBLG Strong Buy
- Analyst Count
- STTK 3
- FBLG 4
- Target Price
- STTK $2.00
- FBLG $13.00
- AVG Volume (30 Days)
- STTK 182.2K
- FBLG 138.6K
- Earning Date
- STTK 02-27-2025
- FBLG 02-02-2025
- Dividend Yield
- STTK N/A
- FBLG N/A
- EPS Growth
- STTK N/A
- FBLG N/A
- EPS
- STTK N/A
- FBLG N/A
- Revenue
- STTK $6,435,000.00
- FBLG N/A
- Revenue This Year
- STTK $313.04
- FBLG N/A
- Revenue Next Year
- STTK N/A
- FBLG N/A
- P/E Ratio
- STTK N/A
- FBLG N/A
- Revenue Growth
- STTK 382.75
- FBLG N/A
- 52 Week Low
- STTK $0.94
- FBLG $1.08
- 52 Week High
- STTK $11.76
- FBLG $46.00
- Technical
- Relative Strength Index (RSI)
- STTK 47.21
- FBLG 40.26
- Support Level
- STTK $1.13
- FBLG $1.86
- Resistance Level
- STTK $1.39
- FBLG $2.13
- Average True Range (ATR)
- STTK 0.11
- FBLG 0.20
- MACD
- STTK -0.00
- FBLG -0.01
- Stochastic Oscillator
- STTK 31.36
- FBLG 8.77
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About FBLG FIBROBIOLOGICS INC
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.